CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 129 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2018. The put-call ratio across all filers is 0.57 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $13,000 | -56.7% | 65,439 | 0.0% | 0.00% | -100.0% |
| Q3 2018 | $30,000 | -9.1% | 65,439 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $33,000 | -83.7% | 65,439 | -24.4% | 0.00% | -85.7% |
| Q1 2018 | $202,000 | -30.8% | 86,505 | -15.9% | 0.01% | 0.0% |
| Q4 2017 | $292,000 | +70.8% | 102,823 | +72.4% | 0.01% | +75.0% |
| Q3 2017 | $171,000 | +375.0% | 59,655 | +311.4% | 0.00% | +300.0% |
| Q2 2017 | $36,000 | -78.7% | 14,499 | -69.7% | 0.00% | -75.0% |
| Q4 2016 | $169,000 | +213.0% | 47,806 | +256.6% | 0.00% | +300.0% |
| Q3 2016 | $54,000 | -18.2% | 13,406 | -11.4% | 0.00% | 0.0% |
| Q2 2016 | $66,000 | -87.5% | 15,137 | -89.1% | 0.00% | -92.3% |
| Q1 2016 | $527,000 | +111.6% | 139,437 | +779.3% | 0.01% | +85.7% |
| Q4 2015 | $249,000 | -68.4% | 15,857 | -44.0% | 0.01% | -72.0% |
| Q1 2015 | $789,000 | – | 28,309 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TSP Capital Management Group, LLC | 813,273 | $3,286,000 | 1.66% |
| RTW INVESTMENTS, LP | 1,243,164 | $5,022,000 | 1.52% |
| Marcus Capital, LLC | 112,200 | $453,000 | 0.44% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 996,178 | $4,024,000 | 0.29% |
| Benchmark Capital Advisors | 67,000 | $271,000 | 0.20% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 360,299 | $1,456,000 | 0.20% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 2,907,523 | $11,746,000 | 0.15% |
| Virtus ETF Advisers LLC | 59,537 | $241,000 | 0.12% |
| Bellevue Group AG | 160,000 | $646,000 | 0.12% |
| PDT Partners, LLC | 428,300 | $1,730,000 | 0.10% |